t-PA trial for central retinal artery occlusion

Examination of effectiveness of tissue plasminogen activator(t-PA) for central retinal artery occlusion(CRAO)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041190079

Enrollment

Registered

2019-11-19

Start date

2020-03-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central retinal artery occlusion artery occlusion

Interventions

After hospitalization, Monteplase prepared as 80000unit/ml with saline is injected into the retinal vessel during vitrectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients older than 20 2.Diagnosed with central retinal artery occulusion within 24 hours 3.Treated with pars plana vitrectomy as an inpatient in this research facility 4.No history of cerebrovascular disease such as stroke, and judged that drug used in this research is not deterioration factor 5.Obtain written informed consent

Exclusion criteria

Exclusion criteria: 1.Expected that the drug influence previous disease 2.central retinal artery occlusion more than 24 hours after the onset 3.Pregnant, possibile pregnancy or hope for pregnancy during the study period

Design outcomes

Primary

Measure	Time frame
Visual acuity at 12 weeks after the first operation	—

Secondary

Measure	Time frame
Changes in visual acuity and central retinal thickness at 12 weeks after the first operation	—

Contacts

Public ContactHayashi Atsushi

Toyama University Hospital

ahayashi@med.u-toyama.ac.jp+81-76-434-7363

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026